MM
MCID: MYL069
MIFTS: 75

Myeloma, Multiple (MM)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Myeloma, Multiple

MalaCards integrated aliases for Myeloma, Multiple:

Name: Myeloma, Multiple 57 36 38
Multiple Myeloma 57 11 19 42 58 75 73 28 5 41 43 14 16 71 31 33
Medullary Plasmacytoma 42 58 71 33
Plasma Cell Myeloma 19 58 53 33
Kahler Disease 19 42 58 33
Myelomatosis 19 42 58 33
Multiple Myeloma, Resistance to 57 12 5
Plasma Cell Dyscrasia 19 42 71
Myeloma 11 53 33
Multiple Myeloma Without Mention of Remission 33
Multiple Myeloma, Susceptibility to 57
Immunoglobulin Deposition Disease 71
Monostotic Plasma Cell Myeloma 33
Primary Systemic Amyloidosis 71
Mm - [multiple Myeloma] 33
Kahler-Bozzolo Disease 42
Plasma Cell Neoplasm 71
Plasma Cell Myelomas 42
Multiple Myeloma Nos 33
Primary Amyloidosis 71
Plasmacytic Myeloma 33
Myeloma - Multiple 19
Multiple Myelomata 33
Kahler's Disease 42
Mm 73

Characteristics:


Inheritance:

Somatic mutation 57

Prevelance:

Multiple Myeloma: 1-9/100000 (United States, Worldwide, France, Europe, United States, Iran, Islamic Republic of, Australia) 1-5/10000 (Europe) 58

Age Of Onset:

Multiple Myeloma: Adult 58

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare haematological diseases


External Ids:

Disease Ontology 11 DOID:9538
OMIM® 57 254500
ICD9CM 34 203.0
MeSH 43 D009101
NCIt 49 C3242
SNOMED-CT 68 94705007
ICD10 31 C90.0
MESH via Orphanet 44 D009101
ICD10 via Orphanet 32 C90.0
UMLS via Orphanet 72 C0026764
Orphanet 58 ORPHA29073
ICD11 33 526287100
UMLS 71 C0026764 C0268381 C0281479 more

Summaries for Myeloma, Multiple

MedlinePlus Genetics: 42 Multiple myeloma is a cancer that develops in the bone marrow, the spongy tissue found in the center of most bones. The bone marrow produces red blood cells, which carry oxygen throughout the body; white blood cells, which form the body's defenses (immune system); and platelets, which are necessary for blood clotting.Multiple myeloma is characterized by abnormalities in plasma cells, a type of white blood cell. These abnormal cells multiply out of control, increasing from about one percent of cells in the bone marrow to the majority of bone marrow cells. The abnormal cells form tumors within the bone, causing bone pain and an increased risk of fractures. If the tumors interfere with nerves near the bones, numbness or weakness in the arms or legs can occur. Affected individuals may also experience a loss of bone tissue, particularly in the skull, spine, ribs, and pelvis. The deterioration of bone can result in an excess of calcium in the blood (hypercalcemia), which can lead to nausea and loss of appetite, excessive thirst, fatigue, muscle weakness, and confusion.The abnormal plasma cells in multiple myeloma produce proteins that impair the development of normal blood cells. As a result, affected individuals may have a reduced number of red blood cells (anemia), which can cause fatigue, weakness, and unusually pale skin (pallor); a low number of white blood cells (leukopenia), which can result in a weakened immune system and frequent infections such as pneumonia; and a reduced number of platelets (thrombocytopenia), which can lead to abnormal bleeding and bruising. Kidney problems can also occur in this disorder, caused by hypercalcemia or by toxic proteins produced by the abnormal plasma cells.People with multiple myeloma typically develop the disorder around age 65. Over time, affected individuals can develop life-threatening complications, but the rate at which this happens varies widely. Some affected individuals are diagnosed incidentally when tests are done for other purposes and do not experience symptoms for years.

MalaCards based summary: Myeloma, Multiple, also known as multiple myeloma, is related to monoclonal gammopathy of uncertain significance and plasma cell neoplasm. An important gene associated with Myeloma, Multiple is LIG4 (DNA Ligase 4), and among its related pathways/superpathways are Breast cancer pathway and MAPK Signaling: Mitogens. The drugs Busulfan and Phentolamine have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are osteopenia and pathologic fracture

MedlinePlus: 41 Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bones. No one knows the exact causes of multiple myeloma, but it is more common in older people and African Americans. It can run in families. Common symptoms may include: Bone pain, often in the back or ribs Fractures (broken bones) Weakness or fatigue Weight loss Frequent infections and fevers Feeling very thirsty Frequent urination Doctors diagnose multiple myeloma using lab tests, imaging tests, and a bone marrow biopsy. Your treatment depends on how advanced the disease is and whether you have symptoms. If you have no symptoms, you may not need treatment right away. If you have symptoms, you may have chemotherapy, stem cell transplantation, radiation, or targeted therapy. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. NIH: National Cancer Institute

GARD: 19 Multiple myeloma is a form of cancer that occurs due to abnormal and uncontrolled growth of plasma cells in the bone marrow. When present, the most common symptom is anemia, which can be associated with fatigue and shortness of breath. Other features of the condition may include multiple infections; abnormal bleeding; bone pain; weak and/or easily broken bones; and numbness and/or weakness of the arms and legs. The exact underlying cause of Multiple myeloma is currently unknown. Factors that are associated with an increased risk of developing Multiple myeloma include increasing age, male sex, African American race, radiation exposure, a family history of the condition, obesity, and/or a personal history of monoclonal gammopathy of undetermined significance (MGUS).

UniProtKB/Swiss-Prot: 73 A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia.

Orphanet: 58 Multiple myeloma (MM) is a malignant tumor of plasma cell characterized by overproduction of abnormal plasma cells in the bone marrow and skeletal destruction. The clinical features are bone pain, renal impairment, immunodeficiency, anemia and presence of abnormal immunoglobulins (Ig).

OMIM®: 57 Multiple myeloma is a neoplastic plasma cell disorder characterized by clonal proliferation of malignant plasma cells in the bone marrow microenvironment, monoclonal protein in the blood or urine, and associated organ dysfunction (Palumbo and Anderson, 2011). (254500) (Updated 08-Dec-2022)

Disease Ontology: 11 A myeloid neoplasm that is located in the plasma cells in bone marrow.

Wikipedia: 75 Multiple myeloma (MM), also known as plasma cell myeloma and simply myeloma, is a cancer of plasma... more...

Related Diseases for Myeloma, Multiple

Diseases related to Myeloma, Multiple via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1791)
# Related Disease Score Top Affiliating Genes
1 monoclonal gammopathy of uncertain significance 33.5 TP53 MIR19A FGFR3 CCND1
2 plasma cell neoplasm 33.3 TP53 PVT1 LIG4 KRAS FGFR3 CCND1
3 leukemia, acute myeloid 32.8 UCA1 TUG1 TP53 MIR93 MIR25 MIR181A2
4 plasmacytoma 32.7 PVT1 GAS5 CCND1
5 leukemia, chronic lymphocytic 32.6 TP53 MIR19A MIR181A2 MIR15A MIR106B KRAS
6 b-cell lymphoma 32.4 TUG1 TP53 PVT1 HOTAIR GAS5 CCND1
7 prostate cancer 32.3 UCA1 TUG1 TP53 PVT1 PCAT1 MIR32
8 renal cell carcinoma, nonpapillary 32.3 UCA1 TUG1 TP53 PVT1 MIR93 MIR25
9 breast cancer 32.3 UCA1 TUG1 TP53 PVT1 MIR93 MIR181A2
10 lymphoma, non-hodgkin, familial 32.2 TP53 MIR93 MIR15A MIR106B CCND1
11 lung cancer 32.2 UCA1 TUG1 TP53 PVT1 PCAT1 MIR93
12 leukemia, chronic myeloid 32.2 UCA1 TP53 MIR19A KRAS HOTAIR CCND1
13 colorectal cancer 32.2 UCA1 TUG1 TP53 PVT1 PCAT1 MIR93
14 hepatocellular carcinoma 32.1 UCA1 TUG1 TP53 PVT1 PCAT1 MIR93
15 melanoma 32.0 UCA1 TP53 PVT1 MIR19A MIR181A2 MIR15A
16 bladder cancer 32.0 UCA1 TUG1 TP53 PVT1 PCAT1 KRAS
17 gastric cancer 32.0 UCA1 TUG1 TP53 PVT1 PCAT1 MIR93
18 lung cancer susceptibility 3 32.0 TUG1 TP53 MIR93 MIR25 MIR15A MIR106B
19 diffuse large b-cell lymphoma 31.9 MIR93 MIR15A MIR106B HOTAIR
20 pancreatic cancer 31.9 UCA1 TUG1 TP53 PVT1 MIR32 MIR25
21 connective tissue disease 31.8 TP53 MIR93 MIR32 MIR25 MIR19A MIR15A
22 osteogenic sarcoma 31.8 UCA1 TUG1 TP53 PVT1 PCAT1 HOTAIR
23 gastrointestinal system disease 31.7 MIR93 MIR25 MIR19A MIR15A MIR106B
24 bone cancer 31.6 TP53 MIR93 MIR32 MIR19A MIR106B CCND1
25 ovarian cancer 31.6 UCA1 TUG1 TP53 PVT1 MIR106B KRAS
26 acute promyelocytic leukemia 31.6 TP53 PVT1 MIR15A KRAS CCND1
27 glioblastoma 31.6 TUG1 TP53 PCAT1 MIR25 MIR181A2 KRAS
28 kidney cancer 31.6 TP53 PVT1 MIR15A MIR106B HOTAIR GAS5
29 cervical cancer 31.6 UCA1 TUG1 TP53 PVT1 PCAT1 MIR93
30 squamous cell carcinoma 31.6 UCA1 TUG1 TP53 PCAT1 KRAS HOTAIR
31 endometrial cancer 31.5 UCA1 TUG1 TP53 KRAS HOTAIR GAS5
32 thyroid carcinoma 31.5 UCA1 PVT1 HOTAIR GAS5
33 retinitis pigmentosa 11 31.5 UCA1 TUG1 TP53 PVT1 MIR25 MIR19A
34 nervous system disease 31.5 TP53 MIR93 MIR32 MIR25 MIR19A MIR15A
35 esophageal cancer 31.5 UCA1 TP53 PVT1 PCAT1 MIR93 MIR106B
36 cholangiocarcinoma 31.4 UCA1 TUG1 TP53 PCAT1 KRAS CCND1
37 colonic benign neoplasm 31.4 TP53 MIR15A KRAS CCND1
38 lymphatic system disease 31.4 TP53 MIR93 MIR25 MIR15A MIR106B
39 spinal disease 31.3 TP53 MIR93 MIR25 MIR19A MIR15A MIR106B
40 chromosome 13q14 deletion syndrome 31.2 TP53 MIR15A
41 gastrointestinal stromal tumor 31.2 TP53 KRAS HOTAIR FGFR3 CCND1
42 brain cancer 31.2 TP53 MIR93 MIR25 MIR19A MIR106B
43 skin disease 31.2 TP53 MIR93 MIR25 KRAS FGFR3 CCND1
44 bladder urothelial carcinoma 31.1 TUG1 TP53 PVT1 KRAS HOTAIR GAS5
45 small cell cancer of the lung 31.1 TUG1 TP53 HOTAIR
46 nasopharyngeal carcinoma 31.1 TP53 PVT1 MIR93 HOTAIR GAS5 CCND1
47 retinal disease 31.1 TP53 MIR25 MIR19A MIR15A MIR106B CCND1
48 esophagus squamous cell carcinoma 31.1 TUG1 PVT1 HOTAIR GAS5 CCND1 CCAT1
49 high grade glioma 31.1 TUG1 TP53 PVT1 HOTAIR GAS5 CCAT1
50 central nervous system disease 31.0 MIR93 MIR25 MIR19A MIR15A MIR106B

Graphical network of the top 20 diseases related to Myeloma, Multiple:



Diseases related to Myeloma, Multiple

Symptoms & Phenotypes for Myeloma, Multiple

Human phenotypes related to Myeloma, Multiple:

58 30 (show all 32)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 osteopenia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000938
2 pathologic fracture 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002756
3 nephropathy 58 30 Frequent (33%) Frequent (79-30%)
HP:0000112
4 fatigue 58 30 Frequent (33%) Frequent (79-30%)
HP:0012378
5 anemia 58 30 Frequent (33%) Frequent (79-30%)
HP:0001903
6 nephrotic syndrome 58 30 Frequent (33%) Frequent (79-30%)
HP:0000100
7 bone pain 58 30 Frequent (33%) Frequent (79-30%)
HP:0002653
8 generalized muscle weakness 58 30 Frequent (33%) Frequent (79-30%)
HP:0003324
9 acute kidney injury 58 30 Frequent (33%) Frequent (79-30%)
HP:0001919
10 hyperproteinemia 58 30 Frequent (33%) Frequent (79-30%)
HP:0002152
11 increased circulating igg level 58 30 Frequent (33%) Frequent (79-30%)
HP:0003237
12 elevated circulating creatinine concentration 30 Frequent (33%) HP:0003259
13 decreased circulating antibody level 30 Frequent (33%) HP:0004313
14 paresthesia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003401
15 abnormality of the bladder 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000014
16 hypercalcemia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003072
17 weight loss 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001824
18 tall stature 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000098
19 functional abnormality of the gastrointestinal tract 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012719
20 spinal cord compression 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002176
21 increased circulating iga level 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003261
22 abnormality of vitamin b12 metabolism 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0004341
23 vertebral compression fracture 30 Occasional (7.5%) HP:0002953
24 splenomegaly 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001744
25 pleural effusion 58 30 Very rare (1%) Very rare (<4-1%)
HP:0002202
26 lymphadenopathy 58 30 Very rare (1%) Very rare (<4-1%)
HP:0002716
27 decreased antibody level in blood 58 Frequent (79-30%)
28 vertebral compression fractures 58 Occasional (29-5%)
29 multiple myeloma 30 HP:0006775
30 amyloidosis 30 HP:0011034
31 elevated serum creatinine 58 Frequent (79-30%)
32 paraproteinemia 30 HP:0031047

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Neoplasia:
multiple myeloma

Laboratory Abnormalities:
paraproteinemia
high m-component
monoclonal gammopathy
primary immunoglobulin-related amyloidosis (al)

Clinical features from OMIM®:

254500 (Updated 08-Dec-2022)

Drugs & Therapeutics for Myeloma, Multiple

Drugs for Myeloma, Multiple (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 610)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Busulfan Approved, Investigational Phase 4 55-98-1 2478
2
Phentolamine Approved Phase 4 50-60-2 5775
3
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
4
Ofloxacin Approved Phase 4 82419-36-1 4583
5
Dimethyl sulfoxide Approved, Vet_approved Phase 4 67-68-5 679
6
Iron Approved Phase 4 7439-89-6 29936
7
Pirarubicin Investigational Phase 4 72496-41-4 4844
8 Vaccines Phase 4
9 Calcium, Dietary Phase 4
10 Antibodies, Anti-Idiotypic Phase 4
11 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
12
Epoetin Alfa Phase 4
13 Hematinics Phase 4
14 Chrysarobin Phase 4
15
Calcium Nutraceutical Phase 4 7440-70-2 271
16
Apixaban Approved Phase 3 503612-47-3 10182969
17
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
18
Melphalan Approved Phase 3 148-82-3 4053 460612
19
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
20
Ondansetron Approved, Withdrawn Phase 3 99614-02-5 4595
21
Heparin, bovine Approved, Investigational, Withdrawn Phase 3 9005-49-6 22833565 9812414 772
22
Denosumab Approved Phase 3 615258-40-7
23
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 3 14838-15-4, 492-39-7 131954576 4786 26934
24
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
25
Morphine Approved, Investigational Phase 3 57-27-2 5288826
26
Pamidronic acid Approved Phase 3 40391-99-9 4674
27
Epirubicin Approved Phase 3 56420-45-2 41867
28
Amitriptyline Approved Phase 3 50-48-6 2160
29
Baclofen Approved Phase 3 1134-47-0 2284
30
Ketamine Approved, Vet_approved Phase 3 6740-88-1, 1867-66-9 3821
31
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2
32
Ifosfamide Approved Phase 3 3778-73-2 3690
33
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1, 93107-08-5 2764
34
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965
35
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
36
Deoxycholic acid Approved Phase 3 83-44-3 222528
37
Carvedilol Approved, Investigational Phase 3 72956-09-3 2585
38
Enalaprilat Approved Phase 3 76420-72-9 6917719 5462501
39
Enalapril Approved, Vet_approved Phase 3 75847-73-3 40466924 5388962 5362032
40
Idarubicin Approved Phase 3 58957-92-9 42890
41
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
42
Vancomycin Approved Phase 3 1404-90-6 14969
43
Tazobactam Approved Phase 3 89786-04-9 123630
44
Piperacillin Approved Phase 3 66258-76-2 43672
45
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
46
Rivaroxaban Approved Phase 2, Phase 3 366789-02-8 9875401
47
Ketorolac Approved Phase 3 74103-06-3, 66635-83-4 3826
48
Hydrocodone Approved, Illicit, Investigational Phase 3 125-29-1 5284569
49
Sodium citrate Approved, Investigational Phase 3 68-04-2 23431961
50
Pancrelipase Approved, Investigational Phase 3 53608-75-6 8519

Interventional clinical trials:

(show top 50) (show all 3096)
# Name Status NCT ID Phase Drugs
1 Doxorubicin Hydrochloride Liposome vs Doxorubicin Combined With Bortizomib and Dexamethasone to Treat Initially Diagnosed Multiple Myeloma: A Randomized Prospective Clinical Study Unknown status NCT02577783 Phase 4 PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone;PAD regimen: bortizomib, dexamethasone and doxorubicin
2 A Multicenter, Double Arms, Prospective Phase 4 Study to Evaluating the Efficacy and Safety of Combination Therapy of PAD Versus VCD Treatment in Previously Untreated Subjects With Multiple Myeloma. Unknown status NCT01868828 Phase 4 PAD;VCD
3 Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients Unknown status NCT04348006 Phase 4 Bortezomib 3.5 MG
4 An Open-Label Phase IV Study of the Efficacy of Bortezomib-based Combination Therapy the Treatment of Subjects With Multiple Myeloma Unknown status NCT02559154 Phase 4 Bortezomib;Dexamethasone;Doxorubicin;Cyclophosphamide;Mitoxsnteone;Thalidomide
5 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
6 Study of Efficacy of PAD-regimen(Bortezomib,Pirarubicin and Dexamethasone) and TAD-regimen(Thalidomide,Pirarubicin and Dexamethasone) in Newly Diagnosed Multiple Myeloma,Influence in Concentration of Bone Metabolites,and the Relations With Different Cytogenetic and Molecular Biological Changes Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
7 A Prospective, Single-Arm, Multicenter, Pragmatic Phase-IV Trial Investigating Safety and Effectiveness of DARZALEX (Daratumumab) In Indian Subjects With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent Completed NCT03768960 Phase 4 Daratumumab
8 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy Completed NCT02958969 Phase 4 Apixaban
9 Thalidomide-Cyclophosphamide-Dexamethasone in Patients < 75 Years or Velcade-Melfalan-Prednisone (V-MP)/Thalidomide-Cyclophosphamide-Dexamethasone in Patients >75 Years, in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide
10 Pharmacokinetic Study of Bortezomib (VELCADE) Administered Intravenously in Taiwanese Patients With Multiple Myeloma - A Post Approval Commitment Study Completed NCT02268890 Phase 4 Bortezomib
11 A Multicenter,Open Label, Randomized Trial Evaluating the Duration of Infusion of Zoledronic Acid 4 mg IV in Multiple Myeloma Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
12 Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Completed NCT03619252 Phase 4 Standard Antibacterial Prophylaxis
13 Assessment of the Antitumour Effect of Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse: Prospective Clinical Trial of the GEM/PETHEMA Group Completed NCT01087008 Phase 4 zoledronic acid
14 A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
15 An Open-label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Completed NCT03416374 Phase 4 Ixazomib;Bortezomib;Carfilzomib;Lenalidomide;Dexamethasone
16 Evaluation of VELCADE (Botezomib) for Injection Employed as Re-Treatment for Efficacy, Safety, and Tolerability Completed NCT00257114 Phase 4 bortezomib
17 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
18 An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures Completed NCT00211211 Phase 4
19 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
20 Bone Marker-directed Dosing of ZOMETA® (Zoledronic Acid) for the Prevention of Skeletal Complications in Patients With Advanced Multiple Myeloma. Completed NCT00622505 Phase 4 zoledronic acid
21 A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone;Melphalan;G-CSF;Cyclophosphamide;Mesna
22 A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety Completed NCT00434447 Phase 4 Zoledronic acid
23 The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia Completed NCT00524407 Phase 4 Epoetin alfa
24 Busulfan Dose Escalation Study Based on AUC in the Setting of Busulfan/Fludarabine Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4 Busulfan;Fludarabine
25 Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults Completed NCT04952766 Phase 4
26 A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) WITH OR WITHOUT DARATUMUMAB (Dara-VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) WITH OR WITHOUT DARATUMUMAB (Dara-Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INELIGIBLE COMMUNITY POPULATION AFFECTED BY MULTIPLE MYELOMA (MM) Recruiting NCT03829371 Phase 4 Velcade;Melphalan;Prednisone;Lenalidomide;Dexamethasone;Daratumumab
27 RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma Recruiting NCT03908138 Phase 4 RDD;VDD
28 A Multicenter, Open-label, Prospective Study of Ixazomib, Lenalidomide, and Ixazomib in Combination With Lenalidomide for Maintenance Therapy in Patients With Newly Diagnosed Multiple Myeloma Recruiting NCT04217967 Phase 4 Ixazomib;Lenalidomide
29 Long-term Follow-up Study for Participants Previously Treated With Ciltacabtagene Autoleucel Recruiting NCT05201781 Phase 4 Cilta-cel
30 Post-marketing Phase 4 Study to Evaluate Safety, Tolerability, and Efficacy of Kyprolis® (Carfilzomib) in Indian Patients With Relapsed or Refractory Multiple Myeloma: A Prospective, Open-label, Non-comparative, Multicenter Study Recruiting NCT03934684 Phase 4 Drug: Carfilzomib + Dexamethasone;Drug: Carfilzomib + Lenalidomide + Dexamethasone
31 A Multi-center, Open-label, Single-arm Clinical Study of Ixazomib/Pomalidomide/Dexamethasone (IxaPD) in the Treatment of Patients With Relapsed Multiple Myeloma Recruiting NCT04989140 Phase 4 Drug: Ixazomib Drug:pomalidomide Drug:dexamethasone
32 A Single Arm, Open Label, Interventional Study Assessing the Mobilization Efficacy and Safety of Plerixafor in Combination With G- CSF in Multiple Myeloma Patients for Autologous Transplantation Recruiting NCT05087212 Phase 4 plerixafor + G-CSF
33 Magnolia Study Prolonged Protection From Bone Disease in Multiple Myeloma. An Open Label Phase 3 Multicenter International Randomised Trial Active, not recruiting NCT02286830 Phase 4 Zoledronic acid
34 An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6) Active, not recruiting NCT03173092 Phase 4 Ixazomib;Lenalidomide;Dexamethasone
35 Influenza Vaccination in Plasma Cell Dyscrasias Active, not recruiting NCT04080531 Phase 4
36 Alternative Dosing Scheme of Pomalidomide 4 mg Every Other Day Versus Pomalidomide 2 mg and 4 mg Every Day: Reduction in Costs, Same Efficacy? A PKPD Bioequivalence Pilot Study; the POMAlternative Study Not yet recruiting NCT05555329 Phase 4 Pomalidomide 4 mg every day in cycle 1;Pomalidomide 4 mg every other day in cycle 2;Pomalidomide 2 mg every day in cycle 2;Pomalidomide 2 mg every day in cycle 3;Pomalidomide 4 mg every other day in cycle 3
37 A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation Not yet recruiting NCT05545202 Phase 4
38 Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury: a Prospective Cohort Study Not yet recruiting NCT05429515 Phase 4 Chemotherapy
39 Clinical, Multicenter, Single-arm, Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma (MM) Newly Diagnosed Symptomatic ≥75 Years Terminated NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
40 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
41 Randomised Controlled Open-label Study to Evaluate Efficacy & Safety of Intravenous Ferric Carboxymaltose Versus no Treatment in Anaemic Subjects With Multiple Myeloma & Iron Restricted Erythropoiesis Receiving Chemotherapy Terminated NCT01100879 Phase 4 Ferric carboxymaltose
42 An Open-Label, Non-Comparative, Two-Cohort, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Pomalidomide and Dexamethasone (IPd, Cohort A) or With Lenalidomide and Dexamethasone (IRd, Cohort B) in Patients With Relapsed/Refractory Multiple Myeloma Previously Receiving a Parenteral Proteasome Inhibitor-based Treatment Regimen (US MM-7) Withdrawn NCT05183139 Phase 4 Ixazomib;Pomalidomide;Lenalidomide;Dexamethasone
43 Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. Withdrawn NCT00242528 Phase 4 Zoledronic acid
44 Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma Withdrawn NCT01410929 Phase 4
45 Phenotypic Personalized Medicine: Systematically Optimized Combination Therapy in Multiple Myeloma Using CURATE.AI Unknown status NCT03759093 Phase 2, Phase 3 Bortezomib;Cyclophosphamide;Dexamethasone;Thalidomide
46 Comparable Investigation of One Fraction Radiotherapy (8 Gy x 1) and Multifraction Radiotherapy (3 Gy x 10) of Painful Bone Destructions in Patients With Multiple Myeloma. Unknown status NCT02024815 Phase 3
47 Myeloma X Relapse (Intensive): A Phase III Study to Determine the Role of a Second Autologous Stem Cell Transplant as Consolidation Therapy in Patients With Relapsed Multiple Myeloma Following Prior High-dose Chemotherapy and Autologous Stem Cell Rescue. Unknown status NCT00747877 Phase 3 cyclophosphamide;melphalan
48 Multizentrische Therapiestudie Des Multiplen Myeloms DSMM V Therapieoptimierungs-Studie Der Deutschen Studiengruppe Multiples Myelom für Patienten Bis 60 Jahre im Stadium II/III Unknown status NCT00546988 Phase 3
49 Allogeneic Bone Marrow Transplantation (Allo-BMT) From Human Leukocyte Antigen (HLA) - Identical Related and Unrelated Donors in Patients With Hematological Malignancies With High Risk of Relapse Using Cyclophosphamide (CY) and Mesenchymal Stromal Cells (MSC) as aGVHD Prophylaxis Unknown status NCT02270307 Phase 2, Phase 3 Cyclophosphamide
50 Clarithromycin Plus CTd (Cyclophosphamide,Thalidomide and Dexamethasone)Regimen for Patients With Newly Diagnosed Multiple Myeloma:a Phase 3 , Multicenter,Randomized, Open-Label Trial. Unknown status NCT02248428 Phase 3 Clarithromycin;Thalidomide;Cyclophosphamide;Dexamethasone

Search NIH Clinical Center for Myeloma, Multiple

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aldesleukin
bortezomib
carfilzomib
Carmustine
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
Melphalan
Melphalan hydrochloride
panobinostat
peginterferon alfa-2a
peginterferon alfa-2b
Procarbazine
Procarbazine Hydrochloride
Recombinant interferon beta-1a
Recombinant interferon beta-1b
Thalidomide
ZOLEDRONIC
zoledronic acid

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myeloma, Multiple cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: multiple myeloma

Genetic Tests for Myeloma, Multiple

Genetic tests related to Myeloma, Multiple:

# Genetic test Affiliating Genes
1 Multiple Myeloma 28 CCND1 LIG4

Anatomical Context for Myeloma, Multiple

Organs/tissues related to Myeloma, Multiple:

FMA: Plasma Cells In Bone Marrow
MalaCards : Bone Marrow, Bone, T Cells, Myeloid, Spinal Cord, Kidney, Nk Cells
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Myeloma, Multiple:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Myeloma, Multiple

Articles related to Myeloma, Multiple:

(show top 50) (show all 38626)
# Title Authors PMID Year
1
Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination. 62 57 5
12471202 2002
2
Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. 62 57 5
9207791 1997
3
IRF4 addiction in multiple myeloma. 53 62 57
18568025 2008
4
Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism. 62 57
28903037 2017
5
BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice. 62 57
27455953 2016
6
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. 62 57
23502783 2013
7
Initial genome sequencing and analysis of multiple myeloma. 62 57
21430775 2011
8
Multiple myeloma. 62 57
21410373 2011
9
Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study. 62 57
19767238 2009
10
A frequent target of paraproteins in the sera of patients with multiple myeloma and MGUS. 62 57
19405124 2009
11
Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. 62 57
18594024 2008
12
Familial myeloma. 62 57
18614782 2008
13
Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes. 62 57
17654686 2007
14
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. 62 57
14739213 2004
15
Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). 62 5
11529856 2001
16
Familial multiple myeloma: report of fifteen families. 62 57
10354144 1999
17
Anticipation in familial plasma cell dyscrasias. 62 57
9858219 1998
18
Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. 62 57
9326949 1997
19
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. 62 57
8943038 1996
20
Multiple myeloma in a pair of twins. 62 57
3814524 1987
21
Multiple myeloma in three siblings. 62 57
3927866 1985
22
Multiple myeloma in a pair of monozygotic twins: the first reported case. 62 57
3925983 1985
23
Familial myeloma. Report of eight families and a study of serum proteins in their relatives. 62 57
4215321 1974
24
Myeloma in mother and daughter. 62 57
4198452 1973
25
MULTIPLE MYELOMA IN SIBLINGS. 62 57
14180901 1964
26
KORNGOLD L: MULTIPLE MYELOMA IN 2 SISTERS. AN IMMUNOCHEMICAL STUDY. 62 57
14172080 1964
27
Multiple myeloma in sisters. 62 57
13766287 1961
28
Multiple myeloma in siblings. 62 57
13563136 1958
29
Familial multiple myeloma. 62 57
13282577 1956
30
No Effect of Vitamin C Administration on Neutrophil Recovery in Autologous Stem Cell Transplantation for Myeloma or Lymphoma: A Blinded, Randomized Placebo-Controlled Trial. 62 41
36432471 2022
31
Prospective Multireader Evaluation of Photon-counting CT for Multiple Myeloma Screening. 62 41
36399038 2022
32
Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma. 62 41
36330523 2022
33
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 5
26619011 2016
34
Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. 62 46
19846888 2009
35
Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. 5
19855393 2009
36
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. 62 46
19401561 2009
37
An epidermal nevus syndrome with cerebral involvement caused by a mosaic FGFR3 mutation. 5
18642369 2008
38
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. 62 46
18728182 2008
39
An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. 62 46
18700954 2008
40
Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. 5
16841094 2006
41
Thanatophoric dysplasia type 2 with encephalocele during the second trimester. 5
16752380 2006
42
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. 5
15772091 2005
43
Guidelines on the diagnosis and management of AL amyloidosis. 57
15180858 2004
44
Somatic and germline mosaicism for a R248C missense mutation in FGFR3, resulting in a skeletal dysplasia distinct from thanatophoric dysplasia. 5
12833394 2003
45
The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum. 5
12624096 2003
46
Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. 57
11972529 2002
47
Prenatal diagnosis of thanatophoric dysplasia by mutational analysis of the fibroblast growth factor receptor 3 gene and a proposed correction of previously published PCR results. 5
10073901 1999
48
Molecular, radiologic, and histopathologic correlations in thanatophoric dysplasia. 5
9677066 1998
49
Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. 57
9482902 1998
50
The systemic amyloidoses. 57
9302305 1997

Variations for Myeloma, Multiple

ClinVar genetic disease variations for Myeloma, Multiple:

5 (show top 50) (show all 198)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 LIG4 NM_206937.2(LIG4):c.8C>T (p.Ala3Val) SNV Protective
7676 rs1805389 GRCh37: 13:108863609-108863609
GRCh38: 13:108211261-108211261
2 LIG4 NM_206937.2(LIG4):c.26C>T (p.Thr9Ile) SNV Protective
7677 rs1805388 GRCh37: 13:108863591-108863591
GRCh38: 13:108211243-108211243
3 KRAS NM_004985.5(KRAS):c.35G>C (p.Gly12Ala) SNV Pathogenic
45122 rs121913529 GRCh37: 12:25398284-25398284
GRCh38: 12:25245350-25245350
4 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His) SNV Pathogenic
Likely Pathogenic
12366 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
5 FGFR3 FGFR3, FGFR3/IGH FUSION VAR Pathogenic
16343 GRCh37:
GRCh38:
6 LIG4 NM_206937.2(LIG4):c.2440C>T (p.Arg814Ter) SNV Pathogenic
7673 rs104894419 GRCh37: 13:108861177-108861177
GRCh38: 13:108208829-108208829
7 FGFR3 NM_000142.5(FGFR3):c.1948A>G (p.Lys650Glu) SNV Pathogenic
16331 rs78311289 GRCh37: 4:1807889-1807889
GRCh38: 4:1806162-1806162
8 FGFR3 NM_000142.5(FGFR3):c.742C>T (p.Arg248Cys) SNV Pathogenic/Likely Pathogenic
16332 rs121913482 GRCh37: 4:1803564-1803564
GRCh38: 4:1801837-1801837
9 TP53 NM_000546.6(TP53):c.841G>A (p.Asp281Asn) SNV Likely Pathogenic
376586 rs764146326 GRCh37: 17:7577097-7577097
GRCh38: 17:7673779-7673779
10 TP53 NM_000546.6(TP53):c.818G>C (p.Arg273Pro) SNV Likely Pathogenic
231060 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
11 TP53 NM_000546.6(TP53):c.743G>C (p.Arg248Pro) SNV Likely Pathogenic
237954 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
12 TP53 NM_000546.6(TP53):c.613T>C (p.Tyr205His) SNV Likely Pathogenic
376685 rs1057520008 GRCh37: 17:7578236-7578236
GRCh38: 17:7674918-7674918
13 TP53 NM_000546.6(TP53):c.712T>C (p.Cys238Arg) SNV Likely Pathogenic
376576 rs1057519981 GRCh37: 17:7577569-7577569
GRCh38: 17:7674251-7674251
14 TP53 NM_000546.6(TP53):c.824G>A (p.Cys275Tyr) SNV Likely Pathogenic
215997 rs863224451 GRCh37: 17:7577114-7577114
GRCh38: 17:7673796-7673796
15 TP53 NM_000546.6(TP53):c.841G>C (p.Asp281His) SNV Likely Pathogenic
376588 rs764146326 GRCh37: 17:7577097-7577097
GRCh38: 17:7673779-7673779
16 TP53 NM_000546.6(TP53):c.713G>T (p.Cys238Phe) SNV Likely Pathogenic
376574 rs730882005 GRCh37: 17:7577568-7577568
GRCh38: 17:7674250-7674250
17 PTPN11 NM_002834.5(PTPN11):c.226G>A (p.Glu76Lys) SNV Likely Pathogenic
13336 rs121918464 GRCh37: 12:112888210-112888210
GRCh38: 12:112450406-112450406
18 TP53 NM_000546.6(TP53):c.395A>G (p.Lys132Arg) SNV Likely Pathogenic
376625 rs1057519996 GRCh37: 17:7578535-7578535
GRCh38: 17:7675217-7675217
19 TP53 NM_000546.6(TP53):c.421T>C (p.Cys141Arg) SNV Likely Pathogenic
376565 rs1057519978 GRCh37: 17:7578509-7578509
GRCh38: 17:7675191-7675191
20 TP53 NM_000546.6(TP53):c.423C>G (p.Cys141Trp) SNV Likely Pathogenic
376564 rs1057519977 GRCh37: 17:7578507-7578507
GRCh38: 17:7675189-7675189
21 TP53 NM_000546.6(TP53):c.842A>G (p.Asp281Gly) SNV Likely Pathogenic
141141 rs587781525 GRCh37: 17:7577096-7577096
GRCh38: 17:7673778-7673778
22 BRAF NM_004333.6(BRAF):c.1787G>T (p.Gly596Val) SNV Likely Pathogenic
40387 rs397507483 GRCh37: 7:140453148-140453148
GRCh38: 7:140753348-140753348
23 TP53 NM_000546.6(TP53):c.742C>G (p.Arg248Gly) SNV Likely Pathogenic
376652 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
24 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Likely Pathogenic
12356 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
25 TP53 NM_000546.6(TP53):c.394A>G (p.Lys132Glu) SNV Likely Pathogenic
376626 rs747342068 GRCh37: 17:7578536-7578536
GRCh38: 17:7675218-7675218
26 TP53 NM_000546.6(TP53):c.451C>T (p.Pro151Ser) SNV Likely Pathogenic
12370 rs28934874 GRCh37: 17:7578479-7578479
GRCh38: 17:7675161-7675161
27 CDK4 NM_000075.4(CDK4):c.70C>T (p.Arg24Cys) SNV Likely Pathogenic
16928 rs11547328 GRCh37: 12:58145431-58145431
GRCh38: 12:57751648-57751648
28 TP53 NM_000546.6(TP53):c.833C>A (p.Pro278His) SNV Likely Pathogenic
376646 rs876659802 GRCh37: 17:7577105-7577105
GRCh38: 17:7673787-7673787
29 TP53 NM_000546.6(TP53):c.815T>G (p.Val272Gly) SNV Likely Pathogenic
233323 rs876660333 GRCh37: 17:7577123-7577123
GRCh38: 17:7673805-7673805
30 TP53 NM_000546.6(TP53):c.451C>G (p.Pro151Ala) SNV Likely Pathogenic
376641 rs28934874 GRCh37: 17:7578479-7578479
GRCh38: 17:7675161-7675161
31 TP53 NM_000546.6(TP53):c.585C>G (p.Ile195Met) SNV Likely Pathogenic
376620 rs1057519994 GRCh37: 17:7578264-7578264
GRCh38: 17:7674946-7674946
32 TP53 NM_000546.6(TP53):c.832C>A (p.Pro278Thr) SNV Likely Pathogenic
376643 rs17849781 GRCh37: 17:7577106-7577106
GRCh38: 17:7673788-7673788
33 BRAF NM_004333.6(BRAF):c.1799T>A (p.Val600Glu) SNV Likely Pathogenic
13961 rs113488022 GRCh37: 7:140453136-140453136
GRCh38: 7:140753336-140753336
34 TP53 NM_000546.6(TP53):c.613T>A (p.Tyr205Asn) SNV Likely Pathogenic
376684 rs1057520008 GRCh37: 17:7578236-7578236
GRCh38: 17:7674918-7674918
35 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Likely Pathogenic
12347 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
36 TP53 NM_000546.6(TP53):c.842A>T (p.Asp281Val) SNV Likely Pathogenic
182968 rs587781525 GRCh37: 17:7577096-7577096
GRCh38: 17:7673778-7673778
37 TP53 NM_000546.6(TP53):c.712T>G (p.Cys238Gly) SNV Likely Pathogenic
376577 rs1057519981 GRCh37: 17:7577569-7577569
GRCh38: 17:7674251-7674251
38 TP53 NM_000546.6(TP53):c.817C>A (p.Arg273Ser) SNV Likely Pathogenic
376656 rs121913343 GRCh37: 17:7577121-7577121
GRCh38: 17:7673803-7673803
39 TP53 NM_000546.6(TP53):c.451C>A (p.Pro151Thr) SNV Likely Pathogenic
12369 rs28934874 GRCh37: 17:7578479-7578479
GRCh38: 17:7675161-7675161
40 TP53 NM_000546.6(TP53):c.583A>T (p.Ile195Phe) SNV Likely Pathogenic
376617 rs942158624 GRCh37: 17:7578266-7578266
GRCh38: 17:7674948-7674948
41 TP53 NM_000546.6(TP53):c.587G>C (p.Arg196Pro) SNV Likely Pathogenic
231165 rs483352697 GRCh37: 17:7578262-7578262
GRCh38: 17:7674944-7674944
42 TP53 NM_000546.6(TP53):c.818G>T (p.Arg273Leu) SNV Likely Pathogenic
376655 rs28934576 GRCh37: 17:7577120-7577120
GRCh38: 17:7673802-7673802
43 TP53 NM_000546.6(TP53):c.832C>G (p.Pro278Ala) SNV Likely Pathogenic
376645 rs17849781 GRCh37: 17:7577106-7577106
GRCh38: 17:7673788-7673788
44 TP53 NM_000546.6(TP53):c.584T>A (p.Ile195Asn) SNV Likely Pathogenic
376618 rs760043106 GRCh37: 17:7578265-7578265
GRCh38: 17:7674947-7674947
45 TP53 NM_000546.6(TP53):c.713G>A (p.Cys238Tyr) SNV Likely Pathogenic
182935 rs730882005 GRCh37: 17:7577568-7577568
GRCh38: 17:7674250-7674250
46 TP53 NM_000546.6(TP53):c.422G>A (p.Cys141Tyr) SNV Likely Pathogenic
140801 rs587781288 GRCh37: 17:7578508-7578508
GRCh38: 17:7675190-7675190
47 TP53 NM_000546.6(TP53):c.743G>T (p.Arg248Leu) SNV Likely Pathogenic
230253 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
48 HRAS, LRRC56 NM_005343.4(HRAS):c.34G>A (p.Gly12Ser) SNV Likely Pathogenic
12602 rs104894229 GRCh37: 11:534289-534289
GRCh38: 11:534289-534289
49 TP53 NM_000546.6(TP53):c.614A>G (p.Tyr205Cys) SNV Likely Pathogenic
376681 rs1057520007 GRCh37: 17:7578235-7578235
GRCh38: 17:7674917-7674917
50 TP53 NM_000546.6(TP53):c.843C>G (p.Asp281Glu) SNV Likely Pathogenic
376587 rs1057519984 GRCh37: 17:7577095-7577095
GRCh38: 17:7673777-7673777

Copy number variations for Myeloma, Multiple from CNVD:

6 (show top 50) (show all 303)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13351 1 1 125000000 Gain Multiple myeloma
2 14061 1 103799708 118390708 Loss Multiple myeloma
3 14338 1 107200000 120600000 Loss and deletion Multiple myeloma
4 14696 1 110000000 184000000 Gain SELL Multiple myeloma
5 16446 1 124300000 247249719 Rearrangement Multiple myeloma
6 17397 1 142600000 155000000 Gain CKS1B Myeloma
7 17400 1 142600000 156500000 Gain and amplification Multiple myeloma
8 17467 1 142902432 245422432 Gain Multiple myeloma
9 20609 1 153300000 154800000 Gain AIM2 Multiple myeloma
10 20611 1 153300000 154800000 Gain SMG5 Multiple myeloma
11 20700 1 1536308 6536308 Loss Multiple myeloma
12 20848 1 154800000 157300000 Gain UFC1 Multiple myeloma
13 20849 1 154800000 158800000 Gain NOS1AP Multiple myeloma
14 20882 1 155000000 156500000 Gain and amplification Multiple myeloma
15 26152 1 197500000 205300000 Gain CHI3L1 Multiple myeloma
16 26153 1 197500000 205300000 Gain PTPN7 Multiple myeloma
17 26162 1 197500000 222100000 Gain GUK1 Multiple myeloma
18 29497 1 23265113 23869113 Loss Multiple myeloma
19 29829 1 236600000 249250621 Gain and amplification Multiple myeloma
20 31636 1 2900000 120700000 Gain CD53 Multiple myeloma
21 31729 1 30200000 32400000 Loss and deletion Multiple myeloma
22 31749 1 30500000 184000000 Gain Multiple myeloma
23 33943 1 50669458 53683458 Loss Multiple myeloma
24 33949 1 50700000 59000000 Loss and deletion Multiple myeloma
25 35189 1 60900000 69500000 Gain NFIA Multiple myeloma
26 36791 1 80821425 83677425 Loss Multiple myeloma
27 36969 1 84171854 96213854 Loss Multiple myeloma
28 37035 1 84700000 88100000 Gain Multiple myeloma
29 37040 1 84700000 94500000 Gain DISC1 Multiple myeloma
30 37519 1 9200000 12700000 Loss and deletion Multiple myeloma
31 37525 10 30762871 30790767 Gain MAP3K8 Multiple myeloma
32 38898 10 105800000 114900000 Loss and deletion Multiple myeloma
33 40402 10 127500000 135534747 Loss and deletion Multiple myeloma
34 41379 10 17300000 22600000 Gain and amplification Multiple myeloma
35 48571 11 100828925 102320925 Loss ANGPTL5 Multiple myeloma
36 48572 11 100828925 102320925 Loss BIRC2 Multiple myeloma
37 48573 11 100828925 102320925 Loss BIRC3 Multiple myeloma
38 48574 11 100828925 102320925 Loss CEP126 Multiple myeloma
39 48575 11 100828925 102320925 Loss MMP1 Multiple myeloma
40 48576 11 100828925 102320925 Loss MMP10 Multiple myeloma
41 48577 11 100828925 102320925 Loss MMP12 Multiple myeloma
42 48578 11 100828925 102320925 Loss MMP13 Multiple myeloma
43 48579 11 100828925 102320925 Loss MMP20 Multiple myeloma
44 48580 11 100828925 102320925 Loss MMP27 Multiple myeloma
45 48581 11 100828925 102320925 Loss MMP3 Multiple myeloma
46 48582 11 100828925 102320925 Loss MMP7 Multiple myeloma
47 48583 11 100828925 102320925 Loss MMP8 Multiple myeloma
48 48584 11 100828925 102320925 Loss TMEM123 Multiple myeloma
49 48585 11 100828925 102320925 Loss TRPC6 Multiple myeloma
50 48586 11 100828925 102320925 Loss YAP1 Multiple myeloma

Expression for Myeloma, Multiple

Search GEO for disease gene expression data for Myeloma, Multiple.

Pathways for Myeloma, Multiple

GO Terms for Myeloma, Multiple

Cellular components related to Myeloma, Multiple according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.47 MIR93 MIR32 MIR25 MIR19A MIR181A2 MIR15A
2 extracellular vesicle GO:1903561 9.26 MIR93 MIR19A MIR15A MIR106B

Biological processes related to Myeloma, Multiple according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 miRNA-mediated gene silencing GO:0035195 9.8 MIR93 MIR32 MIR25 MIR19A MIR181A2 MIR15A
2 negative regulation of gene expression GO:0010629 9.65 TP53 MIR93 MIR19A MIR181A2 MIR106B
3 miRNA-mediated gene silencing by inhibition of translation GO:0035278 9.5 MIR181A2 MIR15A MIR106B
4 negative regulation of interleukin-8 production GO:0032717 9.33 MIR93 MIR181A2 MIR106B
5 response to X-ray GO:0010165 9.1 TP53 LIG4 CCND1

Molecular functions related to Myeloma, Multiple according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.5 TP53 MIR93 MIR19A MIR181A2 MIR15A MIR106B
2 mRNA base-pairing translational repressor activity GO:1903231 9.17 MIR93 MIR32 MIR25 MIR19A MIR181A2 MIR15A

Sources for Myeloma, Multiple

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....